Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-021-21085-8 http://scihub22266oqcxt.onion/10.1038/s41467-021-21085-8 33547300!7864918!33547300     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2021 ; 12 (1): 814 Nephropedia Template TP {{tp|p=33547300|t=2021. Efficacy and tolerability of bevacizumab in patients with severe Covid-19 |pdf=|usr=}}{{33547300}} gab.com Text Efficacy and tolerability of bevacizumab in patients with severe Covid-19 JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33547300 #FOAvip On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesize that the anti-vascular endothelial growth factor (VEGF) drug bevacizumab might be beneficial for treating Covid-19 patients. From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and recruited 26 patients from 2-centers (China and Italy) with severe Covid-19, with respiratory rate >/=30 times/min, oxygen saturation </=93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O(2) ratio (PaO(2)/FiO(2)) >100 mmHg and </=300 mmHg, and diffuse pneumonia confirmed by chest imaging. Followed up for 28 days. Among these, bevacizumab plus standard care markedly improves the PaO(2)/FiO(2) ratios at days 1 and 7. By day 28, 24 (92%) patients show improvement in oxygen-support status, 17 (65%) patients are discharged, and none show worsen oxygen-support status nor die. Significant reduction of lesion areas/ratios are shown in chest computed tomography (CT) or X-ray within 7 days. Of 14 patients with fever, body temperature normalizes within 72 h in 13 (93%) patients. Relative to comparable controls, bevacizumab shows clinical efficacy by improving oxygenation and shortening oxygen-support duration. Our findings suggest bevacizumab plus standard care is highly beneficial for patients with severe Covid-19. Randomized controlled trial is warranted. Twit Text FOAVip Efficacy and tolerability of bevacizumab in patients with severe Covid-19 ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33547300 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33547300 #FOAvip English Wikipedia <ref>{{Cite pmid|33547300}}</ref> Efficacy and tolerability of bevacizumab in patients with severe Covid-19 #MMPMID33547300 Pang J; Xu F; Aondio G; Li Y; Fumagalli A; Lu M; Valmadre G; Wei J; Bian Y; Canesi M; Damiani G; Zhang Y; Yu D; Chen J; Ji X; Sui W; Wang B; Wu S; Kovacs A; Revera M; Wang H; Jing X; Zhang Y; Chen Y; Cao Y Nat Commun 2021[Feb]; 12 (1): 814 PMID33547300show ga On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesize that the anti-vascular endothelial growth factor (VEGF) drug bevacizumab might be beneficial for treating Covid-19 patients. From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and recruited 26 patients from 2-centers (China and Italy) with severe Covid-19, with respiratory rate >/=30 times/min, oxygen saturation 100 mmHg and |*COVID-19 Drug Treatment[MESH] |Aged[MESH] |Angiogenesis Inhibitors/therapeutic use[MESH] |Bevacizumab/*therapeutic use[MESH] |Body Temperature/drug effects[MESH] |COVID-19/virology[MESH] |China[MESH] |Female[MESH] |Fever/prevention & control[MESH] |Humans[MESH] |Italy[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2/*drug effects/physiology[MESH]Efficacy and tolerability of bevacizumab in patients with severe Covid(epmc).pdf DeepDyve Pubget Overpricing